Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and M
Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast r
Despite going virtual due to the COVID-19 pandemic, Jennifer Harris, an immuno-oncology expert from Syneos Health told pharmaphorum’s Richard Staines that the 2020 American Society of Clini
Bristol Myers-Squibb and digital health firm GRYT Health have teamed up to develop an ‘Advocacy Exchange’ virtual platform to unite patient advocacy organisations, patients, policy makers,
Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat
ASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping moments, reports Richard Staines. This time of year oncologists from
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.